- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04105166
Gene Therapy for Pyruvate Kinase Deficiency (PKD)
Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Adult and Pediatric Subjects With PKD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Information
- Phone Number: 646-627-0033
- Email: PKDclinicaltrial@rocketpharma.com
Study Contact Backup
- Name: PKD Clinical Trial
- Email: PKDclinicaltrial@rocketpharma.com
Study Locations
-
-
-
Madrid, Spain, 28009
- Hospital Infantil Universitario Nino Jesus
-
Madrid, Spain
- Hospital Universitario Fundacion Jimenez Diaz
-
-
-
-
California
-
Stanford, California, United States, 94304
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- PKD diagnosis with a confirmed PKLR mutation.
- Adult Cohort ≥18 years old and <50 years for the initial 2 patients enrolled; Pediatric Cohort ≥8-17 years for the next 2-3 patients.
History of severe, transfusion-dependent anemia, defined as:
- At least 6 red blood cell transfusion episodes over a prior 12-month period and Hb levels <9.5 g/dL in the previous 12 months despite splenectomy OR
At least 3 red blood cell transfusion episodes per year over 2 prior years (in the absence of precipitating events such as infection or surgery) and Hb levels <9.5 g/dL in the previous 12 months despite prior splenectomy.
OR
- Hb levels <8.0 g/dL despite prior splenectomy in the absence of transfusions (documented during 2 or more assessments during the prior 1-2 years) regardless of transfusion requirements.
- Adequate cardiac, pulmonary, renal and hepatic function, as detailed in relevant exclusion criteria.
- Availability of detailed medical records, including transfusion requirements, for at least the prior 2 years.
- Willing and able to read and correctly understand the patient information sheet and provide consent (or informed assent for minors) regarding study participation.
- Negative serum pregnancy test for female patients of childbearing potential.
Exclusion Criteria:
- Presence of other known causes of hemolysis (in addition to PKD). Patients with concurrent G6PD deficiency diagnosed during pre-study evaluation may be considered for eligibility if in the opinion of the Investigator, the hemolytic anemia is the result of PKD and the G6PD deficiency is considered an incidental finding.
- A venous thromboembolic event (VTE; i.e., pulmonary embolism or deep vein thrombosis) or arteriothromboembolic event (ATE; including unstable angina, myocardial infarction, stroke or transient ischemic attack) during the prior 12 months.
- Any evidence of severe iron overload that, per Investigator discretion, warrants exclusion.
- Evidence of bridging fibrosis, cirrhosis or active hepatitis on liver biopsy. Liver biopsy is required when liver iron concentration (LIC) is ≥15 mg/g on T2* magnetic resonance imaging (MRI) of liver. If a liver biopsy has been performed less than 6 months prior to enrollment, it does not need to be repeated.
- Significant medical conditions including documented HIV infection, active viral hepatitis, poorly-controlled hypertension, pulmonary hypertension cardiac arrhythmia or congestive heart failure; pulmonary hypertension or ATEs (including stroke or myocardial infarction) within the 6 prior months.
- Active hematologic or solid organ malignancy, not including non-melanoma skin cancer or another carcinoma in situ. Patients with previously resected solid organ malignancies or definitively treated hematologic malignancies may be eligible if there has been no evidence of active malignancy during the prior 3 years.
- Uncontrolled seizure disorder.
- Cardiac T2*<10 ms by magnetic resonance imaging (MRI) or left ventricular ejection fraction (LVEF) <45% by echocardiogram or multiple gated acquisition (MUGA) scanning.
- Hepatic dysfunction as defined by: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5× the upper limit of normal.(ULN).
- Renal dysfunction as defined as serum creatinine > ULN. Patients with creatinine above ULN may be eligible pending documentation of a GFR ≥60 mL/min/1.73m2 as calculated by the Modification of Diet in Renal Disease equation (Stevens 2006), the revised Schwartz formula (for patients under 18 years old) (Schwartz 2009), or 24-hour urine collection.
Pulmonary dysfunction as defined by either:
- Need for supplemental oxygen during the prior 2 weeks (in absence of acute infection) or
- Oxygen saturation (by pulse oximetry) <90%.
- Any medical or other contraindication for both leukapheresis and BM harvest procedure as determined by the treating Investigator.
- Any medical or psychiatric condition that in the opinion of the Investigator renders the subject unfit for trial participation or at higher than acceptable risk for participation.
- Poor functional status, evidenced by Karnofsky Index <70 in adults or Lansky <70 in children.
- Participation in another clinical trial with an investigational drug within 14 days before the informed consent signature. Participation in observational studies is allowed.
- Pregnant women or women with a positive serum pregnancy test at screening or breast feeding or planning to become pregnant within the next 24 months. Women not willing to use highly effective contraceptive methods during the complete study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RP-L301
RP-L301 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
|
Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the safety and toxicity of RP-L301: number of participants with treatment-related adverse events
Time Frame: 2 years
|
The number of participants with treatment-related adverse events as assessed by United States (US) National Cancer Institute (NCI) v.5.0.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transfusion independence
Time Frame: 1 year
|
Transfusion independence (when relevant) at 12 months defined as need for less than or equal to 1 red blood cell transfusion in the previous 6 months
|
1 year
|
Reduction in transfusion requirements
Time Frame: 1 year
|
50% reduction in transfusion requirements (when relevant) at 12 months (assessed in the previous 6 months for the 12-month assessment) relative to the 1-year period prior to enrollment
|
1 year
|
Clinically significant reduction in anemia
Time Frame: 2 years
|
Increase in pre-transfusion hemoglobin (Hb) levels of 1.5 g/dL (determined by 2 assessments separated at least three months over the first and second year of follow up) relative to the average of patient's Hb levels before blood transfusions over the year prior to enrollment OR Increase of at least two-fold in the time to pre-transfusion Hb nadir relative to the average transfusion interval over the year prior to enrollment, where pre-transfusion Hb nadir is defined as the average Hb value (during the year prior to enrollment) prior to red blood cell (RBC) transfusions |
2 years
|
Reduction of hemolysis
Time Frame: 1 year
|
Reduction of reticulocytosis, defined as the number of patients with a reduction of 50% from the average of a patient's absolute reticulocyte counts (obtained prior to therapeutic blood transfusions) over the year prior to enrollment at 12 months subsequent to investigational therapy
|
1 year
|
Genetic correction following administration of RP-L301
Time Frame: 2 years
|
Evidence of multi-lineage gene correction in peripheral blood (PB) and bone marrow (BM cells) will be assessed by measuring vector copy number
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: José Luis López Lorenzo, MD, Hospital Universitario Fundacion Jimenez Diaz
- Principal Investigator: Ami Shah, MD, Stanford University
- Principal Investigator: Julián Sevilla Navarro, MD, PhD, Hospital Universitario Fundacion Jimenez Diaz
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP-L301-0119
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pyruvate Kinase Deficiency
-
Agios Pharmaceuticals, Inc.RecruitingPediatric Pyruvate Kinase Deficiency | Pediatric Hemolytic AnemiaUnited States, Spain, Germany, Netherlands, Canada, France, Israel, Switzerland, Italy
-
Agios Pharmaceuticals, Inc.Enrolling by invitationAnemia, Hemolytic | Pyruvate Kinase DeficiencyJapan
-
Agios Pharmaceuticals, Inc.Active, not recruitingPediatric Pyruvate Kinase Deficiency | Pediatric Hemolytic AnemiaUnited States, Spain, Denmark, Turkey, Netherlands, Czechia, United Kingdom, Germany, Canada, Switzerland
-
Agios Pharmaceuticals, Inc.TerminatedAnemia | Anemia, Hemolytic | Pyruvate Kinase Deficiency | Pyruvate Kinase Deficiency AnemiaUnited States, United Kingdom, Italy, Spain, Netherlands
-
Great Ormond Street Hospital for Children NHS Foundation...National Institute for Health Research, United Kingdom; The Freya FoundationRecruitingPyruvate Dehydrogenase Complex Deficiency | Pyruvate Dehydrogenase E1 Alpha Deficiency | Pyruvate Dehydrogenase E1-Beta Deficiency | Pyruvate Dehydrogenase E2 Deficiency | Pyruvate Dehydrogenase Phosphatase DeficiencyUnited Kingdom
-
Agios Pharmaceuticals, Inc.Active, not recruitingPyruvate Kinase DeficiencyUnited States, Spain, Japan, Canada, United Kingdom, Korea, Republic of, Ireland, Thailand, Italy, Turkey, Denmark, Brazil, France, Germany, Netherlands, Switzerland
-
Agios Pharmaceuticals, Inc.RecruitingPyruvate Kinase DeficiencyUnited States, Germany, Spain, Italy, United Kingdom, Czechia, France, Canada, Korea, Republic of, Netherlands, Turkey, Portugal, Denmark, Ireland, Switzerland, Thailand
-
Agios Pharmaceuticals, Inc.Active, not recruitingPyruvate Kinase DeficiencyUnited States, Canada, Netherlands, United Kingdom, France, Italy
-
Agios Pharmaceuticals, Inc.CompletedAnemia, Hemolytic | Pyruvate Kinase DeficiencyUnited States, United Kingdom, Netherlands, Canada, Denmark, France, Italy, Ireland, Thailand
-
Agios Pharmaceuticals, Inc.CompletedPyruvate Kinase DeficiencyUnited States, Italy, Netherlands
Clinical Trials on RP-L301
-
Ewha Womans UniversityCompletedOsteoarthritisKorea, Republic of
-
European Organisation for Research and Treatment...RecruitingAll Tumor TypesSpain, United Kingdom, Croatia, Belgium, France, Netherlands, Italy, Germany, Portugal, Austria, Cyprus, Czechia, Estonia, Greece, Lithuania, Poland, Romania, Slovenia, Switzerland, Serbia
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)CompletedObsessive-Compulsive DisorderUnited States
-
Repare TherapeuticsDebiopharm International SARecruitingAdvanced Solid TumorUnited States, Canada, Denmark
-
DePuy InternationalTerminated
-
Rocket Pharmaceuticals Inc.RecruitingPKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)United States
-
Rocket Pharmaceuticals Inc.Active, not recruitingFanconi Anemia Complementation Group AUnited States
-
Rocket Pharmaceuticals Inc.California Institute for Regenerative Medicine (CIRM)CompletedLeukocyte Adhesion Defect - Type ISpain, United States, United Kingdom
-
Rocket Pharmaceuticals Inc.Active, not recruitingFanconi Anemia Complementation Group ASpain
-
Rocket Pharmaceuticals Inc.WithdrawnLeukocyte Adhesion Defect - Type ISpain